TNF and psoriasis: As described above, the risk of NMSC and melanoma associated to TNF-α antagonists, such as etanercept, infliximab, and adalimumab has been largely studied in patients with rheumatoid arthritis and Crohn’s disease, and is not established in patients with psoriasis [11].